Edwards Lifesciences Corporation
EW
$79.33
$0.020.03%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.51B | 5.42B | 5.30B | 5.19B | 5.10B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.51B | 5.42B | 5.30B | 5.19B | 5.10B |
| Cost of Revenue | 1.12B | 1.11B | 1.07B | 1.05B | 1.03B |
| Gross Profit | 4.38B | 4.31B | 4.24B | 4.14B | 4.08B |
| SG&A Expenses | 1.82B | 1.78B | 1.71B | 1.67B | 1.63B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -19.40M | -300.00K | -153.60M | -176.00M | -37.00M |
| Total Operating Expenses | 3.97B | 3.94B | 3.64B | 3.56B | 3.60B |
| Operating Income | 1.53B | 1.48B | 1.66B | 1.63B | 1.50B |
| Income Before Tax | 1.61B | 1.55B | 1.52B | 1.51B | 1.40B |
| Income Tax Expenses | 175.80M | 151.80M | 140.80M | 152.80M | 153.40M |
| Earnings from Continuing Operations | 1.43K | 1.39K | 1.38K | 1.36K | 1.24K |
| Earnings from Discontinued Operations | 2.74B | 2.78B | 2.77B | 114.30M | 167.20M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 5.60M | 4.90M | 3.80M | 3.60M | 3.90M |
| Net Income | 4.18B | 4.17B | 4.16B | 1.47B | 1.41B |
| EBIT | 1.53B | 1.48B | 1.66B | 1.63B | 1.50B |
| EBITDA | 1.68B | 1.63B | 1.81B | 1.78B | 1.65B |
| EPS Basic | 7.01 | 6.99 | 6.95 | 2.44 | 2.34 |
| Normalized Basic EPS | 1.74 | 1.67 | 1.84 | 1.77 | 1.63 |
| EPS Diluted | 7.01 | 6.98 | 6.94 | 2.43 | 2.33 |
| Normalized Diluted EPS | 1.73 | 1.67 | 1.83 | 1.77 | 1.63 |
| Average Basic Shares Outstanding | 2.38B | 2.39B | 2.41B | 2.42B | 2.42B |
| Average Diluted Shares Outstanding | 2.38B | 2.40B | 2.41B | 2.42B | 2.43B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |